Catálogo de publicaciones - revistas

<jats:p>The rapid development of COVID-19 vaccines is the outcome of Big Pharma's R&amp;D prowess, billions of dollars in federal investment, and the dedication and ingenuity of scores of scientists. But it also illustrates the logic of the Bayh-Dole Act, passed 40 years ago in the United States, which governs how universities can work with industry to reap the benefits of federally funded research. The act permits universities to collaborate with private companies to license and commercialize these technologies under the rationale that the payoff for the government's investment is increased economic activity for the country. It is unlikely that the act will ever be brought back to the floor of Congress for revision, and its staying power suggests that it is a permanent fixture of the U.S. innovation ecosystem. Nevertheless, there are legitimate philosophical and logistical objections that the incoming administration should work to address.</jats:p>

<jats:p>A roundup of weekly science policy and related news.</jats:p>

<jats:p>People with sickle cell disease or beta-thalassemia could be freed of debilitating symptoms for a lifetime.</jats:p>

<jats:p>Global review of soil biodiversity calls for protecting often overlooked subterranean life.</jats:p>

<jats:p>Biden also picks California attorney general for health and human services.</jats:p>

<jats:p>Genomes show spread of deadly cancer is slowing.</jats:p>

<jats:p>Road map calls for Department of Energy to fund applied as well as basic research.</jats:p>

<jats:p>A €7 billion fund is launched to bolster meager military spending by EU nations.</jats:p>

<jats:p>Psychology's replication crisis inspires efforts to expand samples and stick to a research plan.</jats:p>

<jats:p>Hugo López-Gatell Ramírez's response has drawn criticism and praise.</jats:p>